item: #1 of 61 id: cord-000153-134qz0aw author: Cheung, Benny KW title: A novel anti-mycobacterial function of mitogen-activated protein kinase phosphatase-1 date: 2009-12-17 words: 4339 flesch: 48 summary: Primary human blood monocytes were treated with BCG and assayed for MKP-1 expression. Surprisingly, when MKP-1 expression was blocked by its specific siRNA, there was a significant decrease in the levels of phospho-MAPK (p38 MAPK and ERK1/2) and TNF-α inducible by BCG. keywords: bcg; expression; lps; mapk; p38; results; sirna; tnf cache: cord-000153-134qz0aw.txt plain text: cord-000153-134qz0aw.txt item: #2 of 61 id: cord-002058-rppsmirp author: Carroll, Maria V. title: Identification of four novel DC-SIGN ligands on Mycobacterium bovis BCG date: 2010-09-01 words: 5999 flesch: 46 summary: Bound proteins were eluted with buffer containing EDTA. The Sepharose was placed in a column and washed and bound proteins were eluted with 10 mM Hepes, 140 mM NaCl, 5 mM EDTA pH 7.4. keywords: bcg; binding; bovis; cells; et al; lprg; protein; sign; tuberculosis cache: cord-002058-rppsmirp.txt plain text: cord-002058-rppsmirp.txt item: #3 of 61 id: cord-003504-wjab4y0g author: Copland, Alastair title: Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits date: 2019-03-06 words: 4869 flesch: 40 summary: T cells inhibit effector T cells at the pathological site of miliary tuberculosis Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosisspecific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Mycobacterium tuberculosis-specific CD4+ and CD8+ T cells differ in their capacity to recognize infected macrophages Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: implications for the functional roles of S2 subunit Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages Latency-associated protein Acr1 impairs dendritic cell maturation and functionality: a possible mechanism of immune evasion by Mycobacterium tuberculosis We would like to thank Professor Anne Cooke (University of Cambridge) for kindly providing the MIH5 antibody and for helpful suggestions regarding the in vivo experiments. Cells were stained with a reported competing fluorochrome-conjugated α-PD-L1 clone (10F.9G2) 15 , which binds to the same epitope as MIH5, to test for successful receptor blockade (Fig. 1) . keywords: bcg; blockade; cells; control; expression; fig; macrophages; regulation; stat3 cache: cord-003504-wjab4y0g.txt plain text: cord-003504-wjab4y0g.txt item: #4 of 61 id: cord-005882-iodfgzjf author: Kaufmann, Stefan H E title: Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis date: 2005-04-05 words: 9677 flesch: 35 summary: Could AIDS and tuberculosis vaccines be given together? In contrast, experience with tuberculosis vaccine trials is marginal and currently only a few phase 1 trials have been initiated. keywords: aids; bcg; cd4; cd8; cells; efficacy; hiv; immunity; infection; mice; protection; responses; trials; tuberculosis; vaccination; vaccine; virus cache: cord-005882-iodfgzjf.txt plain text: cord-005882-iodfgzjf.txt item: #5 of 61 id: cord-014712-5u4e00q6 author: None title: Selected Abstracts from the 100th J Project Meeting, Antalya, Turkey, March 12-14, 2014 date: 2014-08-02 words: 36956 flesch: 46 summary: Recurrent severe complicated infections developed in 90% of PID patients. Register for PID patients has been set up in Bulgaria that allowed the collection of data on the incidence and prevalence of PID and the negative effect of these conditions on the population. keywords: age; analysis; antibody; autoimmune; bcg; blood; case; cells; cgd; children; chronic; clinical; cvid; cvid patients; deficiency; diagnosis; disease; disorders; examination; family; findings; gene; group; high; history; hospital; igg; igm; immune; immunodeficiency; immunoglobulin; infections; ivig; laboratory; levels; low; medical; months; mutation; normal; patients; pid; pid patients; present; primary; rate; recurrent; results; scid; skin; study; symptoms; syndrome; therapy; treatment; university; years cache: cord-014712-5u4e00q6.txt plain text: cord-014712-5u4e00q6.txt item: #6 of 61 id: cord-018737-1h84yi2i author: Kumar, Sudeep title: Live-Attenuated Bacterial Vectors for Delivery of Mucosal Vaccines, DNA Vaccines, and Cancer Immunotherapy date: 2019-01-10 words: 10738 flesch: 22 summary: typhimurium Shigella interaction with intestinal epithelial cells determines the innate immune response in shigellosis Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157: H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors 1 Salmonella enterica serovar Tphi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA Adaptation of the endogenous Salmonella enterica serovar Clin Vaccine Immunol CVI Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B An influenza HA and M2e based vaccine delivered by a novel attenuated Salmonella mutant protects mice against homologous H1N1 infection Stable expression of lentiviral antigens by quality-controlled recombinant mycobacterium bovis BCG vectors Recombinant Mycobacterium bovis bacillus Calmette-Guérin expressing Ag85B-IL-7 fusion protein enhances IL-17A-producing innate γδ T cells Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines Concomitant cytosolic delivery of two immunodominant Listerial antigens by Salmonella enterica serovar typhimurium confers superior protection against murine listeriosis An attenuated Listeria monocytogenes vector primes more potent simian immunodeficiency virusspecific mucosal immunity than DNA vaccines in mice Expression of a Porphyromonas gingivalis hemagglutinin on the surface of a Salmonella vaccine vector 1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model Shigella flexneri infection: pathogenesis and vaccine development Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys Oral vaccine of Lactococcus lactis harbouring pandemic H1N1 2009 haemagglutinin1 and nisP anchor fusion protein elevates anti-HA1 sIgA levels in mice Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CTL-immunogen Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis Salmonella typhi and S. typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors Expression of Helicobacter pylori cag12 gene in Lactococcus lactis MG1363 and its oral administration to induce systemic anti-Cag12 immune response in mice Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice Comparison between immunization routes of live attenuated Salmonella typhimurium strains expressing BCSP31, Omp3b, and SOD of Brucella abortus in murine model Cell wall anchoring of the Campylobacter antigens to Lactococcus lactis Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar typhimurium a vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines Salmonella synthesizing 1-monophosphorylated Lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity Turning self-destructing Salmonella into a universal DNA vaccine delivery platform Attenuated shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic escherichia coli Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine strains Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges Brucella lipopolysaccharide reinforced Salmonella delivering Brucella immunogens protects mice against virulent challenge Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus subtilis spore displaying Schistosoma japonicum 26 KDa GST protein Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice Live attenuated Salmonella displaying HIV-1 10E8 epitope on fimbriae: systemic and mucosal immune responses in BALB/c mice by mucosal administration Listeria monocytogenes: a promising vehicle for neonatal vaccination Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery Construction and characterization of recombinant attenuated Salmonella typhimurium expressing the babA2/ureI fusion gene of Helicobacter pylori Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of l-arabinose as inducer of bacterial gene expression in vivo Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica serovar keywords: antigen; bacteria; cells; delivery; dna; enterica; et al; expression; immunity; immunogenicity; listeria; mice; monocytogenes; mucosal; response; salmonella; serovar; strain; system; typhimurium; vaccine; vectors cache: cord-018737-1h84yi2i.txt plain text: cord-018737-1h84yi2i.txt item: #7 of 61 id: cord-024716-1waejlwb author: Roy, Soumya title: Does the Bacillus Calmette–Guérin vaccine provide protection from COVID-19? date: 2020-04-30 words: 1978 flesch: 49 summary: Out of the 21 countries with no universal BCG vaccinations policy, 15 countries had universal BCG vaccination policy in the past but have stopped the practice at present (Group C); five countries never had universal BCG (Group D) and data were not available about one country (San Marino). However, a detailed study into the epidemiological parameters of the countries which had universal BCG vaccination policy in the past (but have stopped universal BCG as of now) revealed enigmatic result. keywords: bcg; countries; group; number cache: cord-024716-1waejlwb.txt plain text: cord-024716-1waejlwb.txt item: #8 of 61 id: cord-208177-m8q6dyfx author: Chaisemartin, Cl'ement de title: BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden date: 2020-06-08 words: 2065 flesch: 45 summary: key: cord-208177-m8q6dyfx authors: Chaisemartin, Cl'ement de; Chaisemartin, Luc de title: BCG vaccination in infancy does not protect against COVID-19. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. keywords: bcg; covid-19; effect; vaccination cache: cord-208177-m8q6dyfx.txt plain text: cord-208177-m8q6dyfx.txt item: #9 of 61 id: cord-252855-xtsnlu1f author: Drago-Serrano, Maria Elisa title: Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections date: 2017-03-01 words: 12051 flesch: 25 summary: Therefore, all findings on Lf activities suggest that Lf and Lfcins can be of potential use as antimicrobial and anti-inflammatory compounds, either alone or as adjuncts to conventional antibiotics and drugs. The reason for the lack of bLf protecting effect in these viral infection mice models is unknown, but possible explanations could be related to timing, dosing, and route of bLf administration. keywords: action; activity; blf; bovine; cells; coli; cytokines; effects; hlf; human; infection; inflammation; iron; lactoferrin; levels; lps; mice; milk; model; response; role; tnfα cache: cord-252855-xtsnlu1f.txt plain text: cord-252855-xtsnlu1f.txt item: #10 of 61 id: cord-256642-payjduek author: Muthuvelu, Sobana title: Measles infection causing Bacillus Calmette-Guérin reactivation: a case report date: 2019-07-24 words: 2784 flesch: 43 summary: Measles infection has not been reported to cause BCG reactivation. We report the unusual finding of BCG reactivation in an infant with laboratory-confirmed measles. keywords: bcg; disease; measles; patient; reactivation; site cache: cord-256642-payjduek.txt plain text: cord-256642-payjduek.txt item: #11 of 61 id: cord-258742-li71b9e0 author: Dolgikh, S. title: Covid-19 Epidemiological Factor Analysis: Identifying Principal Factors with Machine Learning date: 2020-06-05 words: 2032 flesch: 47 summary: The combination of factors was calculated as a sum of factor values (in the cases with very low population density, a correction was added to account for a slower rate of spread as follows: Canada, Australia: 0.2; Finland, Ontario, USA: 0.1; adding the correction does not change the outcome of the analysis essentially). Removing BCG factor results in a reduction of 8.1%. keywords: analysis; factor; preprint; time cache: cord-258742-li71b9e0.txt plain text: cord-258742-li71b9e0.txt item: #12 of 61 id: cord-258877-6hy37qxa author: Dolgikh, S. title: Covid-19 vs BCG Universal Immunization: Statistical Significance at Six Months of Exposure date: 2020-09-08 words: 3862 flesch: 35 summary: https://doi.org/10.1101/2020.09.06.20189423 doi: medRxiv preprint Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study Further evidence of a Possible Correlation Between the Severity of Covid-19 and BCG Immunization Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of BCG vaccination policy and protection against COVID-19 Covid-19 vs BCG: Statistical significance analysis Whole blood profiling of bacillus Calmette-Guérin-induced trained innate immunity in infants identifies epidermal growth factor, IL-6, plate-let-derived growth factor-AB/BB, and natural killer cell activation Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices Canada Covid-19 situation update New York City Covid-19 Updates The BCG vaccine: information and recommendations for use in Australia, The Department of Health WHO immunization estimates Bacillus Calmette-Guérin (BCG) vaccination patterns in the province of BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis Sex-based differences in susceptibility to Severe acute Respiratory Syndrome coronavirus infection Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland The null hypothesis in this case would dictate that immunization should carry no statistical significance for the epidemics impact, and therefore distributions in all of BCG group sample points (A, B, C) as defined above were described by a single distribution with, possibly, time-dependent parameters μ(t), σ(t) that can be estimated from the overall dataset. keywords: bcg; cases; correlation; hypothesis; impact; preprint; time cache: cord-258877-6hy37qxa.txt plain text: cord-258877-6hy37qxa.txt item: #13 of 61 id: cord-260826-1n96pz86 author: Shet, Anita title: Differential COVID-19-attributable mortality and BCG vaccine use in countries date: 2020-04-06 words: 2584 flesch: 30 summary: Recent non-peer reviewed work reported a similar negative association between BCG use and COVID-19 mortality 19 . We surmised that since susceptibility to COVID-19 infection extends to the entire population, crude national COVID-19-specific mortality within the country-specific population would be an informative outcome indicator to study differences in mortality patterns amongst countries, in addition to a priori defined potential exposure variables including BCG vaccine use in national immunization schedules. keywords: bcg; countries; covid-19; disease; mortality; population; preprint cache: cord-260826-1n96pz86.txt plain text: cord-260826-1n96pz86.txt item: #14 of 61 id: cord-263455-dquztf5l author: Schoenmakers, Anne title: The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis date: 2020-10-15 words: 11199 flesch: 42 summary: Cadernos De Saúde Pública BCG vaccination of children against leprosy in Uganda: final results Effectiveness of BCG vaccination among leprosy contacts: a cohort study Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years Comparative leprosy vaccine trial in south India World Health Organization. Results after 10 years Leprosy chemoprophylaxis in Micronesia Eficacia de la rifampicina como profiláctico en contactos de primer orden de lepra A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial Cost-effectiveness of a chemoprophylactic intervention with single dose rifampicin in contacts of new leprosy patients Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention Acceptability of chemoprophylaxis for household contacts of leprosy patients in Bangladesh: a qualitative study Report of the workshop on the use of chemoprophylaxis in the control of leprosy held in Amsterdam, the Netherlands on 14 Prevention of leprosy using rifampicin as chemoprophylaxis Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis Monitoring grade-2 disability rate and applicability of chemoprophylaxis in leprosy control: report of the information consultation Review of leprosy research evidence (2002-2009) and implications for current policy and practice Trend analysis of leprosy in Morocco between 2000 and 2017: evidence on the single dose rifampicin chemoprophylaxis The long term effect of current and new interventions on the new case detection of leprosy: a modeling study Leprosy new case detection trends and the future effect of preventive interventions in Pará State, Brazil: a modelling study Predicting the impact of household contact and mass chemoprophylaxis on future new leprosy cases in South Tarawa, Kiribati: a modelling study Role of contact tracing and prevention strategies in the interruption of leprosy transmission Close contacts with leprosy in newly diagnosed leprosy patients in a high and low endemic area: comparison between Bangladesh and Thailand Chemoprophylaxis: sufficient evidence for starting implementation pilots Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy The leprosy post-exposure prophylaxis (LPEP) programme: update and interim analysis Abstracts of oral presentations -175 feasibility and impact of leprosy post-exposure prophylaxis: evidence from LPEP, a multi-country, 5-year implementation research program Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis An innovative approach to screening and chemoprophylaxis among contacts of leprosy patients in low endemic settings: experiences from Cambodia A single dose of rifampicin to prevent leprosy: qualitative analysis of perceptions of persons affected, contacts, community members and health professionals towards chemoprophylaxis and the impact on their attitudes in India, Nepal and Indonesia Acceptability of contact screening and single dose rifampicin as chemoprophylaxis for leprosy in Dadra and Nagar Haveli Leprosy post-exposure prophylaxis with single-dose rifampicin: toolkit for implementation Minimal essential data to document contact tracing and single dose rifampicin (SDR) for leprosy control in routine settings: a practical guide Global practices in regard to implementation of preventive measures for leprosy Peraturan Menteri Kesehatan Republik Indonesia, Nomor 11 Tahun 2019 Tentang Penanggulangan Kusta Evidence, opportunity, ethics, and the allure of zero leprosy Reply to: single-dose rifampicin and BCG to prevent leprosy Effectiveness of single-dose rifampicin after BCG vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: a cluster randomized controlled trial Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh BCG vaccine and leprosy household contacts: protective effect and probability to becoming sick during follow-up Under-explored experimental topics related to integral mycobacterial vaccines for leprosy Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts Portaria N o keywords: bcg; chemoprophylaxis; contacts; control; disease; effect; exposure; leprosy; patients; pep; post; prevention; research; rifampicin; sdr; study; vaccination; vaccine; years cache: cord-263455-dquztf5l.txt plain text: cord-263455-dquztf5l.txt item: #15 of 61 id: cord-265472-b1s4stvz author: Guimarães, Luísa Eça title: Vaccines, adjuvants and autoimmunity date: 2015-10-31 words: 14650 flesch: 37 summary: An experimental study in Brown Norway rats Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity Six revolutions in vaccinology From Pasteur to genomics: progress and challenges in infectious diseases Systems vaccinology Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century Studies of twins in vaccinology Vaccinomics current findings, challenges and novel approaches for vaccine development The HLA genomic loci map: expression, interaction, diversity and disease The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses Development of polyarthritis after insertion of silicone breast implants followed by remission after implant removal in 2HLA-identical sisters bearing rheumatoid arthritis susceptibility genes Autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination in Colombians: a call for personalised medicine Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits Autoimmunity and hepatitis A vaccine in children Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome Vaccination-induced systemic autoimmunity in farmed Atlantic salmon Autoimmune response following annual influenza vaccination in 92 apparently healthy adults High non-specific T lymphocyte response to the adjuvanted H1N1 vaccine in comparison with the H1N1/H3N2/B-Brisbane vaccine without adjuvant Short and long-term effects of pandemic unadjuvanted influenza A(H1N1) pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine Development of autoantibodies before the clinical onset of systemic lupus erythematosus Genetics and autoantibodies Silicone and autoimmunity Platinum in the environment: frequency of reactions to platinum-group elements in patients with dermatitis and urticaria Silicone and scleroderma revisited Rupture of silicone gel breast implants and symptoms of pain and fatigue This suggests that genomics is crucial in inter-individual variations in vaccine immune responses [82] . keywords: adjuvants; aluminum; anti; antibodies; arthritis; asia; autoimmune; autoimmunity; cases; cell; development; disease; hbv; hepatitis; hpv; human; infection; inflammatory; influenza; patients; response; risk; silicone; specific; studies; syndrome; vaccination; vaccine; virus cache: cord-265472-b1s4stvz.txt plain text: cord-265472-b1s4stvz.txt item: #16 of 61 id: cord-266549-g8060w8v author: Gkentzi, Despoina title: Challenges for the Pediatricians During the Coronavirus Disease 2019 Pandemic Start From the Neonatal Period date: 2020-06-05 words: 1418 flesch: 42 summary: COVID-19 infection does not seem more severe than other CoV or influenza infections in this population, possibly as all infect Angiotensin-Converting Enzyme 2 receptors in the upper airways. We fully agree with the suggested management and approach, although the latter still poses major further logistical issues such as the availability of negative pressure rooms for all inpatients with suspected COVID-19 infection pending virologic confirmation. keywords: bcg; covid-19; infants; infection cache: cord-266549-g8060w8v.txt plain text: cord-266549-g8060w8v.txt item: #17 of 61 id: cord-270675-37kus7mz author: Aziz, Asma Binte title: Debate on Bacille Calmette-Guérin vaccination against COVID-19: Is it worth performing clinical trials? date: 2020-07-09 words: 1242 flesch: 35 summary: Advance online publication Covid-19: what treatments are being investigated Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing Is BCG vaccination causally related to reduced COVID-19 mortality? Biosaf Health DOI: 10.1016/j.bsheal.2020.07.001 sha: doc_id: 270675 cord_uid: 37kus7mz The non-specific beneficial effects of Bacille Calmette-Guérin (BCG) vaccination suggest that this vaccine might play a role in protecting individuals against severe coronavirus disease (COVID-19).Several studies propose that BCG vaccination may increase the body's immunity, thereby preventing respiratory infections caused by other respiratory pathogens. keywords: bcg; covid-19; vaccination cache: cord-270675-37kus7mz.txt plain text: cord-270675-37kus7mz.txt item: #18 of 61 id: cord-271734-1cfhjuxi author: Vergkizi, Souzan title: Bacillus Calmette–Guérin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally date: 2020-10-16 words: 5711 flesch: 42 summary: Following the unresponsiveness of BCG induced cervical lymph nodes to soluble mycobacterial antigens, it was thought worthwhile to check the response of lymph node cells of BCG and M. leprae injected animals to whole BCG organisms. In each group, the first two bars (a, b) correspond to BCG and the last two (c, d) to M. leprae induced lymph node cells. keywords: adherent; bcg; cells; leprae; lymph; macrophages; nodes; non; suppressor cache: cord-271734-1cfhjuxi.txt plain text: cord-271734-1cfhjuxi.txt item: #19 of 61 id: cord-276351-cv5th7hd author: Moorlag, Simone J.C.F.M. title: Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study date: 2020-08-05 words: 1284 flesch: 24 summary: To investigate the safety of BCG vaccination, we retrospectively assessed coronavirus disease 2019 (COVID-19) and related symptoms in three cohorts of healthy volunteers who either received BCG in the last five years or not. BCG vaccination is not associated with increased incidence of symptoms during the COVID-19 outbreak in the Netherlands. keywords: bcg; covid-19; figure; immunity; vaccination cache: cord-276351-cv5th7hd.txt plain text: cord-276351-cv5th7hd.txt item: #20 of 61 id: cord-276495-q22jnkn2 author: Belizário, José Ernesto title: Trained innate immunity, COVID-19 therapeutic dilemma, and fake science date: 2020-07-06 words: 2771 flesch: 37 summary: The objective is to demonstrate whether immunization with BCG vaccines produced using different strains and titers of the bacillus Calmette-Guérin-the vaccine against tuberculosis-can protect these professionals against SARS-CoV-2 infection (3). Clinical trials BRACE (www.clinicaltrialgov, number NCT04327206) and BCG-corona (www.clinicaltrial.gov, number NCT04328 441) are employing large cohorts of health professionals in the Netherlands, Denmark, Germany, England, France, Tanzania, Uganda, Colombia, and Uruguay (3). keywords: bcg; cells; chloroquine; covid-19; memory; patients; treatment; vaccine cache: cord-276495-q22jnkn2.txt plain text: cord-276495-q22jnkn2.txt item: #21 of 61 id: cord-278417-ty4wbtkv author: Chugh, Tulsi title: Timelines of COVID-19 Vaccines date: 2020-07-21 words: 1016 flesch: 48 summary: A comprehensive review of a formidable foe and the road ahead Pandemic preparedness: Developing vaccines and therapeutic antibodies for COVID-19 The early landscape of COVID-19 vaccine development in the UK and rest of the world BCG-induced trained immunity: can it offer protection against COVID-19? BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: A randomized, placebocontrolled pilot study Improved immunotherapy for pulmonary tuberculosis with Mycobacterium Vaccae Effects of Mycobacterial vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Some ecological studies do suggest a link between prior BCG vaccine and recorded cases of COVID-19. keywords: bcg; covid-19; vaccine cache: cord-278417-ty4wbtkv.txt plain text: cord-278417-ty4wbtkv.txt item: #22 of 61 id: cord-279620-ckh4uke6 author: Elenga, Narcisse title: The Imperative of Early Treatment for Children With COVID-19 Infection date: 2020-04-30 words: 940 flesch: 45 summary: By virtue of the NSEs, BCG vaccine has shown to decrease all-cause mortality in children. On critical appraisal of the non-peer reviewed preprint evidence, at the relationship between BCG and COVID-19 is being proven by looking at correlation/ association among two data set (BCG vaccine coverage and COVID-19), without acknowledging the confounders. keywords: bcg; children; covid-19 cache: cord-279620-ckh4uke6.txt plain text: cord-279620-ckh4uke6.txt item: #23 of 61 id: cord-281354-sa27k8o3 author: Takahashi, Harutaka title: Role of Latent Tuberculosis Infections in Reduced COVID-19 Mortality: Evidence from an Instrumental Variable Method Analysis date: 2020-08-26 words: 1441 flesch: 43 summary: A survey of key unpublished and published data regarding the association between BCG vaccination and COVID-19 mortality was conducted, and concluded that there was a lack of evidence to support a protective effect of BCG against COVID-19 This effect has been attributed to innate immune responses induced by BCG vaccination. keywords: bcg; covid-19; mortality cache: cord-281354-sa27k8o3.txt plain text: cord-281354-sa27k8o3.txt item: #24 of 61 id: cord-283603-d6ult65u author: Pasco, Samuel T. title: Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development date: 2020-09-16 words: 6858 flesch: 21 summary: Front The effect of BCG vaccination on alveolar macrophages obtained from induced sputum from healthy volunteers Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 BCG-Induced Trained Immunity in Healthy Individuals: The Effect of Plasma Muramyl Dipeptide Concentrations Vitamin A induces inhibitory histone methylation modifications and down-regulates trained immunity in human monocytes BCG Vaccination in Humans Cell Rep Barillas-Mury, C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) Nonspecific Protection of Mice against Influenza Virus Infection by Local or Systemic Immunization with Bacille Calmette-Guerin Bacillus Calmette-Guérin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response Respiratory Epithelial Cells Can Remember Infection: A Proof of Concept Study Innate activation of human primary epithelial cells broadens the host response to Mycobacterium tuberculosis in the airways Innate Immune Responses after Airway Epithelial Stimulation with Mycobacterium bovis Bacille-Calmette Guérin Mycobacterium tuberculosis Primary Infection and Dissemination: A Critical Role for Comparison of sublingual therapeutic vaccine with antibiotics for the prophylaxis of recurrent urinary tract infections Polybacterial immunomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections Intranasal administration of a polyvalent bacterial lysate induces self-restricted inflammation in the lungs and a Th1/Th17 memory signature Effects of a bacterial extract on local immunity of the lung in patients with chronic bronchitis Local Immunity in Patients with Chronic Bronchitis and the Effects of a Bacterial Extract Stimulation by a bacterial extract (broncho-vaxom) of the metabolic and functional activities of murine macrophages keywords: bcg; cells; effects; immunity; infection; monocytes; mtb; mucosal; protection; responses; stimulation; vaccination; vaccine cache: cord-283603-d6ult65u.txt plain text: cord-283603-d6ult65u.txt item: #25 of 61 id: cord-285306-leu2hygk author: Gallagher, J. title: Association of Bacille Calmette-Guerin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level 4 European countries date: 2020-06-05 words: 2696 flesch: 28 summary: In the best fit model, BCG vaccination score was associated with a 64% reduction in log(10) mortality per 10 million population (OR 0.362 reduction Following adjustment for the effects of population size, median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate, BCG vaccination score remained significantly associated with Covid 19 mortality at day 30. keywords: bcg; day; mortality; population; preprint; vaccination cache: cord-285306-leu2hygk.txt plain text: cord-285306-leu2hygk.txt item: #26 of 61 id: cord-288618-01hxgcds author: Vargas, P. title: Rapid characterization of the propagation of COVID-19 in different countries date: 2020-06-11 words: 4928 flesch: 55 summary: We will extract data from Worldometers for different countries. However, this has not been applied evenly to different countries. keywords: bcg; column; countries; country; gaussian; table; vaccination cache: cord-288618-01hxgcds.txt plain text: cord-288618-01hxgcds.txt item: #27 of 61 id: cord-289008-c4cu3vrp author: Wallis, Christopher J.D. title: Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic date: 2020-05-03 words: 9378 flesch: 41 summary: The timing of radical cystectomy for bacillus Calmette-Guerin failure: comparison of outcomes and risk factors for prognosis Transurethral resection of bladder tumour: the neglected procedure in the technology race in bladder cancer A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients Longer wait times increase overall mortality in patients with bladder cancer Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes Delays in radical cystectomy for muscle-invasive bladder cancer A delay 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging Assessing the impact of time to cystectomy for variant histology of urothelial bladder cancer Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer Radiotherapy with or without chemotherapy in muscleinvasive bladder cancer Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials Advice regarding systemic therapy in patients with urological cancers during the COVID-19 pandemic Cancer statistics Cancer statistics, 2020 Co-morbidities in a retrospective cohort of prostate cancer patients Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer Ten-year mortality, disease progression, and treatmentrelated side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival Timing of curative treatment for prostate cancer: a systematic review Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer While acknowledging the significant psychologic burden associated with a cancer diagnosis, likely magnified by delays in treatment, physicians who treat cancer patients must be good stewards of limited health care resources, particularly in the time of a pandemic. keywords: cancer; carcinoma; covid-19; delays; disease; metastatic; outcomes; patients; risk; studies; survival; therapy; treatment cache: cord-289008-c4cu3vrp.txt plain text: cord-289008-c4cu3vrp.txt item: #28 of 61 id: cord-289742-1usxeo9a author: Riksen, Niels P. title: Immunometabolic control of trained immunity date: 2020-09-02 words: 7684 flesch: 21 summary: Metabolic control by sirtuins and other enzymes that sense NAD(+), NADH, or their ratio Immunometabolic pathways in BCG-induced trained immunity Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis Metabolic induction of trained immunity through the mevalonate pathway In vitro experimental model of trained innate immunity in human primary monocytes Trained innate immunity and atherosclerosis Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo A small jab -a big effect: nonspecific immunomodulation by vaccines Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance mTOR-and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity Western diet triggers NLRP3-dependent innate immune reprogramming Human Bacille Calmette-Guérin vaccination elicits trained immunity via the hematopoietic progenitor compartment Considering BCG vaccination to reduce the impact of COVID-19 The itaconate pathway is a central regulatory node linking innate immune tolerance and trained immunity A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments Trained memory of human uterine NK cells enhances their function in subsequent pregnancies Trained immunity carried by nonimmune cells Induction of memory-like dendritic cell responses in vivo The immunomodulatory potential of the metabolite itaconate Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis Host-directed therapies for bacterial and viral infections Rewiring of glucose metabolism defines trained immunity induced by oxidized low-density lipoprotein The Set7 lysine methyltransferase regulates plasticity in oxidative phosphorylation necessary for trained immunity induced by beta-glucan Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes BCG-induced trained immunity in NK cells: role for non-specific protection to infection Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1 Modulation of myelopoiesis progenitors is an integral component of trained immunity Therapeutic targeting of trained immunity Inflammatory memory sensitizes skin epithelial stem cells to tissue damage Defining trained immunity and its role in health and disease Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection Trained immunity: a memory for innate host defense Beta-glucan reverses the epigenetic state of LPS-induced immunological tolerance Trained immunity characteristics are associated with progressive cerebral small vessel disease A guide to immunometabolism for immunologists Partial inhibition of glycolysis reduces atherogenesis independent of intraplaque neovascularization in mice Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes Antiinflammatory therapy with canakinumab for atherosclerotic disease Trained immunity and atherosclerotic cardiovascular disease Krebs cycle reborn in macrophage immunometabolism Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity Mechanisms of trained innate immunity in oxLDL primed human coronary smooth muscle cells Macrophage fatty-acid synthase deficiency decreases dietinduced atherosclerosis Cholesterol, inflammation and innate immunity Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation Efficacy and safety of low-dose colchicine after myocardial infarction Macrophage immunometabolism: where are we (going)? keywords: cells; cycle; cytokine; et al; glucan; glycolysis; immune; immunity; macrophages; monocytes; pathways; production cache: cord-289742-1usxeo9a.txt plain text: cord-289742-1usxeo9a.txt item: #29 of 61 id: cord-291719-1ku6cmwj author: Hajjo, Rima title: A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality date: 2020-10-06 words: 6506 flesch: 27 summary: Our analysis demonstrates that BCG vaccine affects the production and maturation of naïve T cells resulting in enhanced, long-lasting trained innate immune responses that can provide protection against novel viruses. A consensus gene signature for BCG vaccine was derived from gene expression profiles in peripheral blood mononuclear cells (PBMCs) in response to a BCG challenge test reported by Matsumiya et al (76) , GSE58636 dataset on NCBI Gene Expression Omnibus (GEO) (27) . keywords: bcg; cells; cgs; cov-2; covid-19; effects; expression; gene; network; protein; response; sars; study; vaccination; vaccine cache: cord-291719-1ku6cmwj.txt plain text: cord-291719-1ku6cmwj.txt item: #30 of 61 id: cord-291722-xnfdjriz author: Meenakshisundaram, Ramachandran title: Protective effects of vaccinations and endemic infections on COVID-19: A Hypothesis date: 2020-05-26 words: 840 flesch: 27 summary: Considering BCG vaccination to reduce the impact of COVID-19 Connecting BCG Vaccination and COVID-19: Based on the above, we believe that the above principles may apply for the less occurrence of COVID-19 in regions where other viral infections are prevalent. keywords: bcg; covid-19; infections cache: cord-291722-xnfdjriz.txt plain text: cord-291722-xnfdjriz.txt item: #31 of 61 id: cord-292128-8o20mcur author: Fritschi, Nora title: Bacille Calmette Guérin (BCG) and new TB vaccines: specific, cross-mycobacterial and off-target effects date: 2020-08-20 words: 2477 flesch: 32 summary: Preventing travel-associated 660 tuberculosis in children Mapping the global use of different BCG vaccine strains Genomic expression catalogue of a 667 global collection of BCG vaccine strains show evidence for highly diverged metabolic 668 and cell-wall adaptations BCG -different strains, different vaccines? In addition, the current expert opinion is 221 that BCG vaccine given many years earlier is unlikely to protect against COVID-19 as 222 trained immunity induced by BCG might not be long-lasting and is likely abrogated by other 223 vaccines. keywords: bacille; bcg; calmette; immunisation; tuberculosis; vaccination; vaccine cache: cord-292128-8o20mcur.txt plain text: cord-292128-8o20mcur.txt item: #32 of 61 id: cord-292372-kn27ghlv author: de Chaisemartin, Clément title: BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden date: 2020-08-23 words: 2820 flesch: 50 summary: key: cord-292372-kn27ghlv authors: de Chaisemartin, Clément; de Chaisemartin, Luc title: BCG vaccination in infancy does not protect against COVID-19. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. keywords: bcg; cases; covid-19; effect; vaccination cache: cord-292372-kn27ghlv.txt plain text: cord-292372-kn27ghlv.txt item: #33 of 61 id: cord-294302-hboc3xcz author: Roncati, Luca title: COVID-19 vaccine and boosted immunity: nothing ad interim to do? date: 2020-10-09 words: 2276 flesch: 32 summary: Through C. parvum vaccine (point 3), it is theoretically possible to train and calibrate the immune system towards a T h 1 response (point 4), able to prevent COVID-19 or to keep the disease under control in a paucisymptomatic or asymptomatic way thanks to activated reticuloendothelial system, NK, T c and dendritic cells. In addition, a scientific evidence of C. parvum vaccine protection against a coronavirus (mouse hepatitis virus type 3), dating back to 1981 murine model by Schindler and colleagues, is also reported [31] . keywords: bcg; covid-19; identifier; immune; parvum; vaccine cache: cord-294302-hboc3xcz.txt plain text: cord-294302-hboc3xcz.txt item: #34 of 61 id: cord-298867-hzshnq7b author: Raham, T. F. title: Impact of Duration of Cessation of Mass BCG Vaccination Programs on Covid -19 Mortality date: 2020-08-23 words: 1973 flesch: 39 summary: Looking for duration of cessation of BCG vaccination program as factor is a new idea up to my knowledge to be tested in relation to COVID-19 mortality supporting the hypotheses of effectiveness of BCG vaccinations programs in prevention of COVID-19 mortality. Recommendations: Decisions on BCG vaccination program cessation might be en reconsidered. keywords: bcg; preprint; vaccination cache: cord-298867-hzshnq7b.txt plain text: cord-298867-hzshnq7b.txt item: #35 of 61 id: cord-298945-0sm0r4v8 author: Kuratani, N. title: Association of national Bacille Calmette-Guerin vaccination policy with COVID-19 epidemiology: an ecological study in 78 countries date: 2020-05-16 words: 1344 flesch: 50 summary: Using publicly accessible databases, I explored associations of national BCG vaccination policy with COVID-19 epidemiology in 78 countries. Using publicly accessible databases, I explored associations of national BCG vaccination policy with COVID-19 epidemiology in 78 countries. keywords: bcg; countries; preprint cache: cord-298945-0sm0r4v8.txt plain text: cord-298945-0sm0r4v8.txt item: #36 of 61 id: cord-299676-6wt9rn1a author: Gursel, Mayda title: Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic? date: 2020-04-27 words: 998 flesch: 38 summary: Of interest, in a randomized placebo-controlled human study, BCG vaccination was demonstrated to induce epigenetic reprograming in monocytes, conferring protection against experimental infection with an attenuated yellow fever virus vaccine strain. Results showed that COVID-19associated deaths relative to the size of the population were significantly lower in countries with a national BCG vaccination programme than those without BCG vaccination (P<0.0058 and P<0.0001 for 23 March and 29, 31 March, respectively). keywords: bcg; countries; vaccination cache: cord-299676-6wt9rn1a.txt plain text: cord-299676-6wt9rn1a.txt item: #37 of 61 id: cord-300338-duhyb754 author: Urashima, Mitsuyoshi title: BCG Vaccination and Mortality of COVID-19 across 173 Countries: An Ecological Study date: 2020-08-03 words: 5682 flesch: 39 summary: An ecological study was conducted by obtaining data of 61 factors in 173 countries, including BCG vaccine coverage (%), using morbidity and mortality as outcomes, obtained from open resources. Only countries that had data of both total deaths and BCG vaccine coverage were included for analyses in this study. keywords: bcg; countries; covid-19; morbidity; mortality; pcr; population; tests; vaccine cache: cord-300338-duhyb754.txt plain text: cord-300338-duhyb754.txt item: #38 of 61 id: cord-300729-35meen0h author: Miller, Aaron title: Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study date: 2020-03-28 words: 2744 flesch: 45 summary: key: cord-300729-35meen0h authors: Miller, Aaron; Reandelar, Mac Josh; Fasciglione, Kimberly; Roumenova, Violeta; Li, Yan; Otazu, Gonzalo H title: Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study date: 2020-03-28 journal: nan DOI: 10.1101/2020.03.24.20042937 sha: doc_id: 300729 cord_uid: 35meen0h COVID-19 has spread to most countries in the world. establishment of universal BCG vaccination and the mortality rate, consistent with the idea that the earlier that a policy was established, the larger fraction of the elderly population would be protected (see Figure 2 , left panel). keywords: bcg; countries; covid-19; policy; vaccination cache: cord-300729-35meen0h.txt plain text: cord-300729-35meen0h.txt item: #39 of 61 id: cord-304108-kn9v8qmz author: Aksu, Kurtuluş title: Factors determining COVID‐19 pneumonia severity in a country with routine BCG vaccination date: 2020-08-19 words: 2651 flesch: 40 summary: This is the first study to evaluate severity of clinical condition with BCG-vaccination status in Population characteristics of countries such as population density, median age, and urban population and mainly SARS-CoV-2 test rates are major confounders that may lead to misjudgement of BCG vaccination policy is beneficial. All rights reserved Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination Mandated Bacillus CalmetteGuérin (BCG) vaccination predicts flattened curves for the spread of Epidemiological Determinants of Acute Respiratory Syndrome Coronavirus-2 Disease Pandemic and The Role of the Bacille Vaccine in Reducing Morbidity and Mortality The influence of BCG immunisation on tuberculin reactivity and booster effect in adults in a country with a high prevalence of tuberculosis Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Chinese Center for Disease Control and Prevention Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States Accepted Article coronavirus disease 2019: keywords: bcg; covid-19; disease; patients; pneumonia; study; vaccination cache: cord-304108-kn9v8qmz.txt plain text: cord-304108-kn9v8qmz.txt item: #40 of 61 id: cord-305264-0uhabgsr author: Weng, C-H. title: Bacillus Calmette–Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study date: 2020-07-09 words: 1530 flesch: 45 summary: patients had BCG vaccination. Individuals with BCG vaccination were less likely to require hospital admission during the disease course (3.7% vs. 15.8%, P = 0.019). keywords: bcg; covid-19; patients; vaccination cache: cord-305264-0uhabgsr.txt plain text: cord-305264-0uhabgsr.txt item: #41 of 61 id: cord-309888-93rdcwrh author: Tamás, Fazekas title: COVID-19 research: promising tracks leading to uro-oncology date: 2020-05-11 words: 1786 flesch: 40 summary: Protection of BCG vaccination against viral infections has also been described for Herpes and Influenza viruses [8] . Based on these findings, the Murdoch Children's Research Institute in Australia and the Radboud University in the Netherland have launched prospective clinical trials enrolling health care workers, to assess whether BCG vaccination protects against Sars-CoV-2 infection or reduces its severity [11, 12] . keywords: bcg; cancer; covid-19; sars; tmprss2; vaccination cache: cord-309888-93rdcwrh.txt plain text: cord-309888-93rdcwrh.txt item: #42 of 61 id: cord-314121-ez62fx9p author: de Chaisemartin, C. title: BCG vaccination in infancy does not protect against COVID-19. Evidence from a natural experiment in Sweden. date: 2020-06-23 words: 2903 flesch: 52 summary: key: cord-314121-ez62fx9p authors: de Chaisemartin, C.; de Chaisemartin, L. title: BCG vaccination in infancy does not protect against COVID-19. We used regression discontinuity to assess the effect of BCG vaccination on Covid-19 related outcomes. keywords: bcg; covid-19; medrxiv; preprint; vaccination cache: cord-314121-ez62fx9p.txt plain text: cord-314121-ez62fx9p.txt item: #43 of 61 id: cord-315101-7mim3yl6 author: Kumar Gupta, Pramod title: New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19? date: 2020-07-28 words: 1236 flesch: -30 summary: Recent reports have suggested that BCG vaccination might have protective effects against COVID-19, however it is highly unlikely that BCG vaccine in its current form can offer complete protection against SARS-CoV-2 infection due to the lack of specific immunity. Remdesivir and 337 chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro A Genomic Perspective on the Origin and Emergence of SARS-CoV-2, Cell The epidemiology and pathogenesis of coronavirus disease (COVID-19) 342 outbreak A pneumonia outbreak associated with a 346 new coronavirus of probable bat origin SARS-CoV-2 Vaccines: Status Report Origin and evolution of pathogenic coronaviruses A new coronavirus 352 associated with human respiratory disease in China SARS and MERS: recent insights into 354 emerging coronaviruses Characterization of the receptor-356 binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral 357 attachment inhibitor and vaccine Structure, Function, and 359 Antigenicity of the SARS-CoV-2 Spike Glycoprotein A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2, Cell host 363 & microbe Non-specific effects of BCG vaccine on viral 365 infections, Clinical microbiology and infection : the official publication of the European Society of Clinical 366 Microbiology and Infectious Diseases BCG Vaccination Protects against Experimental Viral Infection in Humans through 370 the Induction of Cytokines Associated with Trained Immunity Nonspecific effects of vaccines and the reduction of mortality in children BCG-Induced Cross-Protection and Development of Trained 376 Immunity: Implication for Vaccine Design BCG vaccination scar associated with better childhood survival in Guinea-Bissau, 379 Randomized trial of BCG vaccination at birth 382 to low-birth-weight children: beneficial nonspecific effects in the neonatal period? Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination 386 at first health center contact Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-389 Bissau: a beneficial effect of BCG vaccination for girls community based case-control study, Vaccine Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with 392 superficial bladder cancer? keywords: bcg; effects; immunity; vaccination; vaccine cache: cord-315101-7mim3yl6.txt plain text: cord-315101-7mim3yl6.txt item: #44 of 61 id: cord-318542-785hnh19 author: Leeson, Cale E. title: Systematic Review: Safety of Intravesical Therapy for Bladder Cancer in the Era of COVID-19 date: 2020-08-18 words: 2672 flesch: 34 summary: [9] Intravesical BCG treatment in immunocompromised patients remains a relative contraindication in some guidelines 7 , while its role in the treatment of acute immunological disorders remains uncertain. We aim to review and summarize what is known about COVID-19 and the current implications of intravesical BCG with regard to the disease. keywords: bcg; bladder; cancer; covid-19; disease; patients cache: cord-318542-785hnh19.txt plain text: cord-318542-785hnh19.txt item: #45 of 61 id: cord-323141-6z750avb author: Kuroda, Naoto title: Demand for BCG Vaccine Due to Unproven Claims of its Role in Preventing COVID-19 Is Causing Shortages of Vaccines for Infants in Japan date: 2020-12-05 words: 1762 flesch: 47 summary: SARS-CoV-2 infection in a pediatric department in Milan: a logistic rather than a clinical emergency Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn Antibodies in infants born to mothers with COVID-19 pneumonia Coronavirus infections in children including COVID-19 an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children Guidelines for pregnant women with suspected SARS-CoV-2 infection Can a century-old TB vaccine steel the immune system against the new coronavirus? Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study Immune boost against the corona virus [Max-Planck-GesellSchaft web site The environment and disease: association or causation Opinion about effectiveness of BCG vaccine against COVID-19 Apprehension regarding BCG shortage led the Japanese Society for Vaccinology to officially state that it does not recommend the use of BCG vaccine for the prevention of COVID-19. keywords: bcg; care; covid-19; data; infection cache: cord-323141-6z750avb.txt plain text: cord-323141-6z750avb.txt item: #46 of 61 id: cord-325966-0g7a9s5z author: Shih, Hsin-I. title: Fighting COVID-19: a quick review of diagnoses, therapies, and vaccines date: 2020-05-30 words: 7334 flesch: 33 summary: For COVID-19 patients, fever and cough are the two most common symptoms, and some patients might also suffer from sputum production, sore throat, headache, myalgia/arthralgia, rhinorrhea, and diarrhea An earlier study demonstrated that hydroxychloroquine was significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect was strengthened by azithromycin [25] . keywords: antibodies; bcg; cells; coronavirus; cov-2; covid-19; immunity; infection; patients; protein; rna; sars; syndrome; treatment; vaccination; vaccine; virus cache: cord-325966-0g7a9s5z.txt plain text: cord-325966-0g7a9s5z.txt item: #47 of 61 id: cord-328262-hw8swbt5 author: O’Neill, Luke A. J. title: BCG-induced trained immunity: can it offer protection against COVID-19? date: 2020-05-11 words: 2180 flesch: 33 summary: Clinical features of patients infected with 2019 novel coronavirus in Wuhan The non-specific effects of vaccines Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs Non-specific effects of BCG vaccine on viral infections Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes Trained immunity: a program of innate immune memory in health and disease BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? COVID-19: consider cytokine storm syndromes and immunosuppression The authors contributed equally to all aspects of the article. Interestingly, however, soon after its introduction in Europe in the 1920s, epidemiological studies reported that BCG vaccination strongly reduced infant mortality, and this could not be explained by a reduction in tuberculosis alone (reviewed previously 2 ). keywords: bcg; covid-19; immunity; infections; vaccination cache: cord-328262-hw8swbt5.txt plain text: cord-328262-hw8swbt5.txt item: #48 of 61 id: cord-328623-ud8vz3zu author: Raham, T. F. title: Malaria Endemicity Influence on COVID -19 Mortality: New Evidence Added to BCG and TB Prevalence date: 2020-09-11 words: 2018 flesch: 36 summary: BCG BCG through attenuated strain of Mycobacterium bovis was used to produce heterogeneous immunity against Mycobacterium tuberculosis , another species within the genus Mycobacterium. In spite of that, many countries discontinue BCG vaccinations or limited its use to high risk groups because great achievements in reduction of TB prevalence rates in these countries. keywords: bcg; factor; malaria; mortality cache: cord-328623-ud8vz3zu.txt plain text: cord-328623-ud8vz3zu.txt item: #49 of 61 id: cord-330203-7xen4nlm author: Joy, Melvin title: Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries date: 2020-09-05 words: 1171 flesch: 50 summary: The objective of our study was to determine the association between BCG vaccine coverage and incidence of COVID-19 at a national-level across the Globe. The objective of our study was to determine the association between BCG vaccine coverage and incidence of COVID-19 at a national-level across the Globe. keywords: bcg; coverage; covid-19 cache: cord-330203-7xen4nlm.txt plain text: cord-330203-7xen4nlm.txt item: #50 of 61 id: cord-331477-2x9szmjc author: Warnakulasuriya, Saman title: Protecting dental manpower from COVID‐19 infection date: 2020-06-01 words: 1877 flesch: 46 summary: Dental patients could have a strong urge to spit after a procedure. While the transmission of COVID 19 via human ex-haled droplets and direct contact is clear, the potential for aerosol transmission is a significant risk particularly for dental practices. keywords: bcg; covid-19; oral; patients; symptoms; vaccine cache: cord-331477-2x9szmjc.txt plain text: cord-331477-2x9szmjc.txt item: #51 of 61 id: cord-334550-xb0alubj author: Samaddar, Arghadip title: The Enigma of Low COVID-19 Fatality Rate in India date: 2020-07-28 words: 6415 flesch: 38 summary: Researchers from Translational Bioinformatics Group at International Center for Genetic Engineering and Biotechnology (ICGEB) in collaboration with the Department of Biochemistry, Jamia Hamdard, New Delhi, India, performed an integrated mutational analysis of SARS-CoV-2 genomes from different geographical locations, including India, Italy, United States, Nepal and Wuhan, and observed a novel mutation in S protein (A930V, 24351C>T) of the Indian strain, which was absent in other strains (Sardar et al., 2020) . Genomic sequence data indicate that SARS-CoV-2 has 96.2% sequence homology with a bat coronavirus RaTG13 (Zheng, 2020) , and 91% homology with a pangolin coronavirus (Zhang et al., 2020) . keywords: bcg; cells; coronavirus; cov-2; covid-19; disease; et al; human; indian; mutations; population; sars; strains; virus cache: cord-334550-xb0alubj.txt plain text: cord-334550-xb0alubj.txt item: #52 of 61 id: cord-338498-3238fz73 author: Kleen, Thomas-Oliver title: Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends” date: 2020-09-04 words: 12549 flesch: 26 summary: bioRxiv Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Immune responses to middle east respiratory syndrome coronavirus during the acute and convalescent phases of human infection Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clonally diverse CD38(+)HLA-DR(+)CD8(+) T cells persist during fatal H7N9 disease Characterization of human CD8 T cell responses in dengue virusinfected patients from India Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses Human Ebola virus infection results in substantial immune activation This is further supported by a study that screened for the presence of SARS-specific T cells in a cohort of three SARS-CoV-recovered individuals, where CD8+ T cell responses targeting the SARS-CoV membrane and nucleocapsid proteins were found to persist up to 11 years post-infection (70) . keywords: activation; acute; bcg; cd8; cells; coronavirus; cov-2; covid-19; disease; human; immune; immunity; infection; innate; macrophages; patients; responses; sars; study; t cells; vaccine cache: cord-338498-3238fz73.txt plain text: cord-338498-3238fz73.txt item: #53 of 61 id: cord-340532-fpmd9nzf author: Ventura, L. title: BCG vaccination and socioeconomic variables vs Covid-19 global features: clearing up a controversial issue date: 2020-05-26 words: 3096 flesch: 40 summary: key: cord-340532-fpmd9nzf authors: Ventura, L.; Vitali, M.; Romano Spica, V. title: BCG vaccination and socioeconomic variables vs Covid-19 global features: clearing up a controversial issue date: 2020-05-26 journal: nan DOI: 10.1101/2020.05.20.20107755 sha: doc_id: 340532 cord_uid: fpmd9nzf Background: The Covid-19 pandemic is characterized by extreme variability in the outcome distribution and mortality rates across different countries. Some recent studies suggested an inverse correlation with BCG vaccination at population level, while others denied this hypothesis. keywords: bcg; countries; license; medrxiv; preprint; vaccination cache: cord-340532-fpmd9nzf.txt plain text: cord-340532-fpmd9nzf.txt item: #54 of 61 id: cord-342847-sjcanw19 author: Leung, Andrea S title: Novel genome polymorphisms in BCG vaccine strains and impact on efficacy date: 2008-09-15 words: 6124 flesch: 48 summary: Our previous study [35] and current work provide direct evidence that BCG vaccine strains are different in major virulence factors, and likely have different vaccination properties including safety, immunogenicity, and efficacy. Our study demonstrates that major virulence factors are different among BCG strains, which provide molecular mechanisms for important vaccine phenotypes including adverse effect profile, tuberculin reactivity and protective efficacy. keywords: bcg; bovis; deletion; genome; is6110; mycobacterium; phop; phor; strains; tuberculosis; vaccine; virulence cache: cord-342847-sjcanw19.txt plain text: cord-342847-sjcanw19.txt item: #55 of 61 id: cord-344553-uya1j94u author: Bodova, K. title: Time-adjusted Analysis Shows Weak Associations Between BCG Vaccination Policy and COVID-19 Disease Progression date: 2020-05-06 words: 3864 flesch: 41 summary: No evidence from a regression discontinuity analysis Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing Johns Hopkins University Novel Coronavirus (COVID-19) Cases Data Application of BCG vaccine for immune-prophylaxis among Egyptian healthcare workers during the pandemic of COVID-19 Patterns of the COVID19 epidemic spread around the world: exponential vs power laws Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data Differences in power-law growth over time and indicators of COVID-19 pandemic progression worldwide Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study Non-specific effects of BCG vaccine on viral infections Early epidemiological assessment of the virulence of emerging infectious diseases: a case study of an influenza pandemic CSV mit den aktuellen Covid-19 Infektionen pro Tag (Zeitreihe) Using a delay-adjusted case fatality ratio to estimate under-reporting. key: cord-344553-uya1j94u authors: Bodova, K.; Boza, V.; Brejova, B.; Kollar, R.; Mikusova, K.; Vinar, T. title: Time-adjusted Analysis Shows Weak Associations Between BCG Vaccination Policy and COVID-19 Disease Progression date: 2020-05-06 journal: nan DOI: 10.1101/2020.05.01.20087809 sha: doc_id: 344553 cord_uid: uya1j94u In this study, we ascertain the associations between BCG vaccination policies and progression of COVID-19 through analysis of various time-adjusted indicators either directly extracted from the incidence and death reports, or estimated as parameters of disease progression models. keywords: bcg; cases; countries; covid-19; number; policies; time; vaccination cache: cord-344553-uya1j94u.txt plain text: cord-344553-uya1j94u.txt item: #56 of 61 id: cord-345114-b06uz0sj author: Klinger, Danielle title: Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis date: 2020-07-11 words: 6993 flesch: 46 summary: Supplementary Materials: The following are available online at http://www.mdpi.com/2076-393X/8/3/378/s1, Figure S1 : correlation of BCG years of admission and COVID-19 outcomes for countries bounded by a population size of >100 M, Figure S2 : results from a multivariable analysis for countries bounded by a population size of >100 M, Table S1 : variable resources across countries and populations, Table S2 : additional resources on BCG administration years by country, Table S3 : country cohort of 55 countries used in the study, Table S4 : correlations and p-values of regression of years of BCG administrations and different outcomes including permutation tests, Table S5 : multivariable results at numerous time points for BCG years of admission, Table S6 : Sub-sampling of countries for years of BCG administration and COVID-19 outcome, Text S1: The results from multivariable regression tests with 23 economic, demographic, health-related, and pandemic restriction-related quantitative properties, substantiate the dominant contribution of BCG years to the COVID-19 outcomes. keywords: age; bcg; correlation; countries; covid-19; dpm; figure; group; population; years cache: cord-345114-b06uz0sj.txt plain text: cord-345114-b06uz0sj.txt item: #57 of 61 id: cord-350103-liwvhuzj author: Brooks, Nathan A. title: The role of the urologist, BCG vaccine administration, and SARS‐CoV‐2: An overview date: 2020-06-22 words: 2853 flesch: 33 summary: Specifically, the epidemiologic evidence for decreased COVID‐19 morbidity in countries with BCG vaccination programs, current clinical trials for BCG vaccination to protect against COVID‐19, potential mechanisms and rationale for this protection, and the role of the urologist and urology clinic in providing support and/or leading ongoing efforts. Emerging evidence suggests that BCG vaccination might reduce the rate of infection and mitigate the rate of mortality in countries with BCG vaccination programs. keywords: bcg; bladder; cancer; countries; covid-19; infection; vaccination; vaccine cache: cord-350103-liwvhuzj.txt plain text: cord-350103-liwvhuzj.txt item: #58 of 61 id: cord-351002-msjurww1 author: Ouanes, Y. title: Does BCG protect against SARS-CoV-2 infection ?: elements of proof. date: 2020-05-06 words: 2998 flesch: 48 summary: Results : Countries that never had universal BCG vaccination policy have a higher mortality (correlated to performed diagnostic tests) attributed to SARS-CoV-2 infection (p<0.001). Countries that never had universal BCG vaccination policy have a higher mortality (correlated to performed diagnostic tests) attributed to SARS-CoV-2 infection (p<0.001). keywords: bcg; countries; preprint; vaccination cache: cord-351002-msjurww1.txt plain text: cord-351002-msjurww1.txt item: #59 of 61 id: cord-354972-nc496v6s author: Margolin, Emmanuel title: Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa date: 2020-09-10 words: 10934 flesch: 27 summary: The host immune response in respiratory virus infection: balancing virus clearance and immunopathology Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Disappearance of antibodies to SARS-associated coronavirus after recovery Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome Positive RT-PCR test results in patients recovered from COVID-19 Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Molecular mechanism for antibodydependent enhancement of coronavirus entry Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE) Several strategies may improve the magnitude and durability of vaccine responses in individuals infected with HIV-1, such as higher doses, booster immunizations and/or the use of adjuvants 127 . keywords: africa; cases; coronavirus; countries; cov-2; covid-19; development; disease; individuals; infection; pandemic; patients; responses; risk; sars; south; spike; testing; trial; tuberculosis; vaccine; virus cache: cord-354972-nc496v6s.txt plain text: cord-354972-nc496v6s.txt item: #60 of 61 id: cord-355384-qa7grviy author: NaserEddin, Adeeb title: Bacillus Calmette–Guerin (BCG) Vaccine-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation date: 2020-10-27 words: 4280 flesch: 36 summary: BCG vaccines: Their mechanisms of attenuation and impact on safety and protective efficacy BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies Bacille Calmette-Guerin vaccine-induced disease in HIVinfected and HIV-uninfected children Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study Primary Immunodeficiency Diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency Immunologic aspects of patients with disseminated bacille Calmette-Guerin disease in north-west of Iran Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs) Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity Defining combined immunodeficiency Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors1 Deep intronic mis-splicing mutation in JAK3 gene underlies T-B+NK-severe combined immunodeficiency phenotype Severe cutaneous bacillus Calmette-Guérin infection in immunocompromised children: the relevance of skin biopsy Successful treatment of BCG-related immune reconstitution inflammatory syndrome following ex vivo T-cell-depleted haploidentical hematopoietic stem cell transplantation: a case report Primary immunodeficiency diseases and Bacillus Calmette-Guérin (BCG)-vaccine-derived complications: a systematic review An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication Hematopoietic stem cell transplantation for children with primary immunodeficiency diseases: single center experience in Jordan Successful handling of disseminated BCG disease in a child with severe combined immunodeficiency Disseminated bacillus Calmette-Guérin infection and immunodeficiency Successful bone marrow transplantation and treatment of BCG infection in two patients with severe combined immunodeficiency An intensive approach to the treatment of disseminated BCG infection in a SCID patient BCG-related inflammatory syndromes in severe combined immunodeficiency after TCRαβ+/CD19+ depleted HSCT Successful unrelated mismatched cord blood transplantation in an infant with severe combined immunodeficiency and Mycobacterium bovis bacillus Calmette-Guèrin disease Disseminated BCG infection following bone marrow transplantation for X-linked severe combined immunodeficiency Disseminated BCG infection in severe combined immunodeficiency presenting with severe anaemia and associated with gross hypersplenism after bone marrow transplantation Expansion of γδt cells in an infant with severe combined immunodeficiency syndrome after disseminated BCG infection and bone marrow transplantation Molecular diagnosis of severe combined immunodeficiencyidentification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children Successful management of cutaneous BCG dissemination in a child affected by SCID and receiving allogeneic hematopoietic stem cell transplant Successful second bone marrow transplantation in Omenn's syndrome after bone marrow aplasia: a case report Hemophagocytic bone marrow aplasia with plasma cells in a RAG2-deficient SCID case after a nonconditioned transplantation from a fully matched sibling Bacillus calmette-guerin infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation Successful unrelated cord blood stem cell transplantation in an X-linked chronic granulomatous disease patient with disseminated BCG-induced infection Immune Responses to Bacillus Calmette-Guérin vaccination: why do they fail to protect against Mycobacterium tuberculosis? We recorded baseline patient characteristics, timing, and nature of BCG complications, prophylactic and treatment regimens, immunological work up, transplant characteristics, and outcome. keywords: bcg; bcgosis; cell; complications; hsct; immunodeficiency; infection; patients; post; transplant cache: cord-355384-qa7grviy.txt plain text: cord-355384-qa7grviy.txt item: #61 of 61 id: cord-355926-24z5lhet author: Meena, Jitendra title: BCG Vaccination Policy and Protection Against COVID-19 date: 2020-06-09 words: 503 flesch: 49 summary: Among the countries with universal BCG vaccination policy (n-142), a weak but positive correlation (spearmen rho-0.1-0.5, p < 0.05) was observed between COVID-19 cases and deaths per million population and BCG vaccination coverage rates (Supplementary Table 1 ). Out of 170 countries for which data on BCG vaccination and COVID-19 was available, we excluded 28 countries (<100 cases as on May 13, 2020). keywords: bcg; covid-19 cache: cord-355926-24z5lhet.txt plain text: cord-355926-24z5lhet.txt